Webinar: First void urine & HPV genotyping - Two essential tools to monitor the impact of HPV vaccination programs

Senior project coordinator/researcher @University of Antwerp

After his studies as Bioengineer at Free University of Brussels, 1989, he followed a postgraduate course on Tropical Veterinary Medicine at Tropical Medicine Institute of Antwerp (ITG). Since 2001 he works as senior project coordinator and researcher at the University of Antwerp within the Centre for the Evaluation of Vaccination. He is involved in several vaccine preventable disease projects including the Viral Hepatitis Prevention board. Since 2015 he also coordinates the activities of the Human Papilloma Virus Prevention and Control board. In 2016 he obtained his Phd Medical Sciences on detection of HPV DNA in urine and monitoring the impact of HPV vaccination. In 2020 he is nominated associated Professor and coordinates a research team that further investigates the use of first void urine as a liquid biomarker for follow-up of vaccination programs, cervical screening programs and genital tract infections in women.

Marketing Manager @Fujirebio Europe

Rebecca obtained a master degree in Industrial Engineering - Biochemistry and Biotechnology at the University of Applied Science in Ghent in 1996. She mastered her molecular techniques as a scientific collaborator at the laboratory of pharmaceutical Biotechnology performing human identification using DNA profiling techniques, mainly for the department of Justice in Belgium. In 1998 she started her career at Innogenetics as a product specialist and post market surveillance coordinator. Since 2017 she is marketing manager at Fujirebio, which acquired Innogenetics in 2010. In this role, she supports Fujirebio’s automated CLEIA products, the INNO-strip-based immunoassays and molecular diagnostics with main expertise in Infectious Diseases.

Senior Product Manager @Novosanis

David Faster graduated in 2004 as a Bio-Engineer, after studying at the Catholic University of Leuven. Shortly after, he started his professional career in the pharmaceutical industry, first in a Quality/Operations role at Schering-Plough (currently Merck, Sharpe & Dohme) and then later on as a validation engineer for Johnson & Johnson in the Janssen Beerse site. In 2014, he traded the pharmaceutical industry for Biocartis, a molecular diagnostics company. He started out for the first two years supporting new product introductions, after which he led the customer service department for 3 years. After one year working as a CRM consultant, David returned to the life science industry earlier this year, joining Novosanis as their senior product manager. He is supporting the further commercialization and expansion of the Colli-Pee product family.